Ionis Pharmaceuticals announced that the U.S. FDA has accepted for review a New Drug Application for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy. The application has been given a Prescription Drug User Fee Act action date of Dec. 22, 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IONS:
- RXDX vs. IONS: Which Biotech Stock is Better?
- Ionis Pharmaceuticals price target lowered to $27 from $34 at SVB Securities
- Ionis Pharmaceuticals price target lowered to $40 from $44 at Barclays
- Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M
- Ionis Pharmaceuticals reports Q4 EPS (37c), consensus (92c)